Blood Res.  2015 Mar;50(1):63-65. 10.5045/br.2015.50.1.63.

Atypical HUS caused by anti-complement factor H antibody: a hematologist's perspective

• Kumar M
• Mandal P
• De R
• Mukherjee
• Dolai TK
• Bhattyacharyya M

• KMID: 1787918
• DOI: http://doi.org/10.5045/br.2015.50.1.63

Abstract

No abstract available.

MeSH Terms

Complement Factor H*
Complement Factor H

Figure

• 

  Fig. 1 Peripheral smear showing many fragmented cells and spherocytes.

• 

  Fig. 2 Trend of improvement in platelet count (×109/L) and creatinine (mg/dl) after starting daily plasma exchange.

Reference

1. Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011; 6:60. PMID: 21902819.

2. Loirat C, Saland J, Bitzan M. Management of hemolytic uremic syndrome. Presse Med. 2012; 41:e115–e135. PMID: 22284541.

3. Dragon-Durey MA, Loirat C, Cloarec S, et al. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2005; 16:555–563. PMID: 15590760.

4. Garg AX, Suri RS, Barrowman N, et al. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA. 2003; 290:1360–1370. PMID: 12966129.

5. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, et al. French Society of Pediatric Nephrology. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2007; 18:2392–2400. PMID: 17599974.

6. Caprioli J, Noris M, Brioschi S, et al. International Registry of Recurrent and Familial HUS/TTP. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006; 108:1267–1279. PMID: 16621965.

7. Ariceta G, Besbas N, Johnson S, et al. European Paediatric Study Group for HUS. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol. 2009; 24:687–696. PMID: 18800230.

8. Taylor CM, Machin S, Wigmore SJ, Goodship TH. working party from the Renal Association, the British Committee for Standards in Haematology and the British Transplantation Society. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol. 2010; 148:37–47. PMID: 19821824.

9. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006; 355:1233–1243. PMID: 16990386.

10. Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med. 2009; 360:544–546. PMID: 19179329.

11. Nürnberger J, Philipp T, Witzke O, et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med. 2009; 360:542–544. PMID: 19179328.